# GKB Ophthalmics (NSE: GKB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/GKB · Pivot · prices to 22 Oct 2026

GKB Ophthalmics (NSE: GKB) closed at ₹60.00 on 22 Oct 2026, up 0.00% on the day. With a market capitalisation of ₹30 Cr, it ranks 3368th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the FMCG sector; its industry is Medical Instruments & Supplies.

At its last close the stock traded at 24.8× trailing earnings, against a return on equity of 2.3% in FY26. Its 52-week range is ₹58.10 (21 Oct 2026) to ₹76.02 (22 Sep 2026); the last close is 21.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹30 Cr (−4.0% year on year) and net profit ₹1 Cr, on a consolidated basis. Promoters held 51.15% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹60.00 |
| Market cap | ₹30 Cr |
| P/E (trailing) | 24.8 |
| ROE | 2.3% (FY26) |
| ROCE | 12.5% (FY26) |
| Debt to equity | 0.22 |
| 52-week high | ₹76.02 (22 Sep 2026) |
| 52-week low | ₹58.10 (21 Oct 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹30 Cr | −4.0% | ₹1 Cr | — | ₹0.38 |
| Q3 FY26 | ₹57 Cr | +120.1% | ₹1 Cr | — | ₹0.88 |
| Q2 FY26 | ₹30 Cr | +15.4% | ₹2 Cr | — | ₹3.17 |
| Q1 FY26 | ₹32 Cr | +24.2% | −₹1 Cr | — | −₹2.02 |
| Q4 FY25 | ₹31 Cr | +43.9% | −₹4 Cr | — | −₹7.03 |
| Q3 FY25 | ₹26 Cr | +7.3% | −₹2 Cr | — | −₹4.03 |
| Q2 FY25 | ₹26 Cr | +28.1% | −₹1 Cr | — | −₹2.41 |
| Q1 FY25 | ₹26 Cr | +16.9% | −₹0 Cr | −107.3% | ₹0.50 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹109 Cr | −₹7 Cr |
| FY24 | ₹88 Cr | −₹3 Cr |
| FY23 | ₹75 Cr | ₹0 Cr |
| FY22 | ₹71 Cr | ₹2 Cr |
| FY21 | ₹57 Cr | −₹1 Cr |
| FY20 | ₹58 Cr | −₹2 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 51.15%
- Foreign institutions: 1.79%
- Non-institutions: 47.07%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Paos Industries](https://app.pivotnow.in/stock/PAOS) | — | ₹30 Cr | — | — |
| [Sinnar Bidi](https://app.pivotnow.in/stock/SINNAR) | — | ₹30 Cr | — | — |
| [Times Green](https://app.pivotnow.in/stock/TIMESGREEN) | — | ₹30 Cr | — | — |
| [Tyroon Tea](https://app.pivotnow.in/stock/TYROON) | — | ₹30 Cr | — | — |
| [Ambo Agritec](https://app.pivotnow.in/stock/AMBOAGRI) | — | ₹29 Cr | — | — |
| [Chordia Food](https://app.pivotnow.in/stock/CHORDIA) | — | ₹29 Cr | — | — |

## Questions and answers

### What is the share price of GKB Ophthalmics today?

GKB Ophthalmics (NSE: GKB) last closed at ₹60.00 on 22 Oct 2026. Its 52-week high is ₹76.02 and its 52-week low is ₹58.10.

### What is the market cap of GKB Ophthalmics?

GKB Ophthalmics' market capitalisation is ₹30 Cr (₹30 Cr) at the 22 Oct 2026 close, ranking 3368th among the NSE companies Pivot tracks.

### What is the P/E ratio of GKB Ophthalmics?

GKB Ophthalmics trades at a trailing P/E of 24.8.

### What is the ROE and ROCE of GKB Ophthalmics?

Return on equity was 2.3% in FY26 and return on capital employed was 12.5% in FY26 (consolidated figures).

### Is GKB Ophthalmics a debt-free company?

No. GKB Ophthalmics' debt-to-equity ratio was 0.22 in FY26, with total debt of ₹2 Cr.

### What were GKB Ophthalmics' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), GKB Ophthalmics reported revenue of ₹30 Cr, −4.0% year on year, and net profit of ₹1 Cr.

### What is the shareholding pattern of GKB Ophthalmics?

As of 30 Jun 2026: promoters 51.15%, foreign institutions 1.79%, non-institutions 47.07%.

### Who are GKB Ophthalmics' competitors?

The listed FMCG companies closest to GKB Ophthalmics by market cap are Paos Industries, Sinnar Bidi, Times Green, Tyroon Tea, Ambo Agritec and Chordia Food.

### Is GKB Ophthalmics a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out GKB Ophthalmics' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GKB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.